Drug Combination Details
General Information of the Combination (ID: C24621) | |||||
---|---|---|---|---|---|
Name | Vinblastine NP Info | + | Nanoliposomal C6-ceramide Drug Info | ||
Structure | + | ||||
Disease |
Colon cancer
[ICD-11: 2B90]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
|
In-vitro Model | LS174T | CVCL_1384 | Colon adenocarcinoma | Homo sapiens | ||
Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
In-vivo Model | Tumor cells were inoculated into the left flank of 7 week-old female athymic nude mice by subcutaneous injection of 6 * 106 LS174T cells in 0.1 mL Hanks Balanced Salt Solution. | |||||
Experimental
Result(s) |
In vitro and in vivo data support a synergistic antitumor activity of the nanoliposomal C6-ceramide and vinblastine combination, potentially mediated by an autophagy mechanism. |